Table 3.
Adjusted odds ratios of outcomes in the phase 1 adopter sites after the HCPP was adopted, accounting for secular trend of non-adopter sites (difference-in-difference analysis)
| Entire post-period (Jan 2018–Mar 2019) | Post-period “pilot” (Jan–Jun 2018) | Post-period “maintenance” (Jul 2018–Mar 2019) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Na | aORb (95% CI) | p value | N | aOR (95% CI) | p value | N | aOR (95% CI) | p value | |
| Process measures | |||||||||
| BP recheckc | 29,994 | 3.52 (3.3–3.76) | <0.001 | 18,529 | 2.43 (2.23–2.63) | <0.001 | 22,648 | 4.7 (4.36–5.06) | <0.001 |
| 90-day follow-upd | 33,997 | 1.06 (1–1.13) | 0.07 | 20,750 | 1.06 (0.98–1.14) | 0.1 | 24,482 | 1.06 (0.98–1.15) | 0.1 |
| Clinical outcomes: | |||||||||
| BP control | 40,688 | 1.11 (1.07–1.15) | <0.001 | 31,464 | 1.08 (1.03–1.13) | <0.001 | 35,398 | 1.14 (1.08–1.19) | <0.001 |
| Non-severely elevated BP | 40,688 | 1.12 (1.05–1.19) | <0.001 | 31,464 | 1.09 (1.01–1.17) | 0.03 | 35,398 | 1.14 (1.06–1.23) | <0.001 |
aNumber of patients
baOR, adjusted odds ratios, determined from coefficient of interaction term (pathway status × post-period) with 3 post HCPP periods evaluated relative to pre-period: post-HCPP pilot period (6 months after HCPP adoption), maintenance period (7–15 months after HCPP adoption), and pilot and maintenance period combined (entire period)
cBP recheck, same-day blood pressure (BP) recheck among those with an elevated BP measurement
dAt least one BP measurement in the same site within 90 days of a confirmed elevated BP; the post-period ends in December 2018 for this outcome to allow for a 90-day follow-up period
*Only evaluated among the subset of patients with medication data within a year before and after the adoption of the HCPP